Mabpharm Limited (HKG:2181)
0.5500
-0.0100 (-1.79%)
At close: Mar 27, 2026
Mabpharm Revenue
In the year 2025, Mabpharm had annual revenue of 646.10M CNY with 150.20% growth. Mabpharm had revenue of 274.18M in the half year ending June 30, 2025, with 522.86% growth.
Revenue
646.10M CNY
Revenue Growth
+150.20%
P/S Ratio
3.15
Revenue / Employee
1.69M CNY
Employees
383
Market Cap
2.27B HKD
Revenue Chart
* This company reports financials in CNY.
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | 646.10M | 387.87M | 150.20% |
| Dec 31, 2024 | 258.23M | 171.07M | 196.27% |
| Dec 31, 2023 | 87.16M | 31.24M | 55.87% |
| Dec 31, 2022 | 55.92M | -26.96M | -32.53% |
| Dec 31, 2021 | 82.88M | - | - |
| Dec 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Frontage Holdings | 1.99B |
| Hangzhou Jiuyuan Genetic Biopharmaceutical | 1.43B |
| Medtide | 546.29M |
| Cutia Therapeutics | 374.07M |
| ImmuneOnco Biopharmaceuticals (Shanghai) | 171.70M |
| Antengene Corporation | 117.22M |
| Zhaoke Ophthalmology | 35.58M |
| Jiangsu Recbio Technology | 14.16M |